TENK
TenX Keane Acquisition

409
Mkt Cap
$139.47M
Volume
94,284.00
52W High
$6.19
52W Low
$0.5506
PE Ratio
-8.77
TENK Fundamentals
Price
$1.57
Prev Close
$1.67
Open
$1.66
50D MA
$1.84
Beta
-2.35
Avg. Volume
263,343.39
EPS (Annual)
-$0.3108
P/B
3.69
Loading...
Loading...
News
all
press releases
News Placeholder
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc...
PR Newswire·1y ago
News Placeholder
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates PR Newswire CRANFORD, N.J., July 10, 2024...
PR Newswire·1y ago
News Placeholder
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and...
PR Newswire·1y ago
News Placeholder
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and...
PR Newswire·2y ago

Latest TENK News

View

Advertisement|Remove ads.

Advertisement|Remove ads.